JBJ-04-125-02 T11714
Specifications
| 1mg/5mg/10mg/25mg/50mg/100mg |
Bioactivity:
JBJ-04-125-02 can inhibit cancer cell proliferation and EGFRL858R/T790M/C797S signaling. JBJ-04-125-02 has anti-tumor activities. JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858
CAS nr:
2060610-53-7
Purity:
98%
Molecular Weight:
543,61
SMILES:
O=C(NC1=NC=CS1)[C@@H](C2=CC(F)=CC=C2O)N(CC3=C4C=C(C5=CC=C(N6CCNCC6)C=C5)C=C3)C4=O
Formula:
C29H26FN5O3S
Pathway:
Angiogenesis,JAK/STAT signaling,Chromatin/Epigenetic,Stem Cells
Target:
JAK,JAK,JAK,JAK
